Company Profile
NuCana plc Stock Price, News & Catalysts
- Ticker:
- NCNA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
1.52 USD (-0.65%)
Close
Last updated: August 21, 2026
8.62M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, NCNA closed down 0.65% at $1.52. No new same-company headline was identified in the current news window.
Company overview
ProTide Oncology Company
NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells.
NUC-7738
NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor microenvironment. It is being evaluated with pembrolizumab in PD-1-inhibitor-resistant melanoma.
NUC-3373
NUC-3373 is a targeted thymidylate-synthase inhibitor designed to overcome pharmacologic limitations of established fluoropyrimidine therapies.
Combination Development
NuCana is evaluating tumor types and drug combinations that could support future registrational strategies for both NUC-7738 and NUC-3373.
Future catalysts
- Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 in melanoma during 2026.
- FDA guidance on a potential registrational strategy for NUC-7738 in melanoma during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NuCana plc (NCNA)?
NuCana plc (NCNA) most recently closed at 1.52 USD, a -0.65% move versus the previous session.
What is the market cap of NuCana plc (NCNA)?
NuCana plc currently has a market capitalization of 8.62M USD on BioPharmSignal.
What does NuCana plc do?
ProTide Oncology Company NuCana applies its ProTide chemistry platform to transform nucleoside analogs into medicines designed to generate higher concentrations of active anticancer metabolites inside tumor cells. NUC-7738 NUC-7738 is a ProTide that disrupts RNA polyadenylation and affects multiple components of the tumor microenvironment. It is being...
On which exchange is NCNA stock listed?
NuCana plc (NCNA) is associated with NASDAQ, United Kingdom, Biopharma.
What is NUC-7738?
Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 in melanoma during 2026.
Which conditions is NuCana plc targeting with NUC-7738?
NuCana plc is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does NuCana plc describe recent progress with NUC-7738?
Final data from the Phase 2 NuTide:701 expansion study of NUC-7738 in melanoma during 2026.
What is PD-1?
It is being evaluated with pembrolizumab in PD-1-inhibitor-resistant melanoma.